Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiying Qiu

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Annals of Hematology|November 20, 2025
Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter studyYuqing Tu, Lingyi Yang, Yaxin Cheng, et al.
Blood Advances|February 27, 2026
VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem CellsQiaomei He, Xi Sun, Lin Veronica Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Annals of Hematology|November 20, 2025
Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter studyYuqing Tu, Lingyi Yang, Yaxin Cheng, et al.
Blood Advances|February 27, 2026
VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem CellsQiaomei He, Xi Sun, Lin Veronica Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 20